Randomized clinical trial participation does not impact dialysis facility quality scores
Click Here to Manage Email Alerts
Patients meet clinical quality targets equally at dialysis facilities that participate vs. centers that do not participate in randomized clinical trials, according to presented research.
“The global burden of chronic kidney disease is higher than most chronic diseases,” Kurt Mussina, MBA, said at the American Nephrology Nurses Association National Symposium, adding that the approximately 5% of chronic kidney disease cases that progress to end-stage renal disease “is attributable to almost 1 million deaths each year, and it is the only chronic condition universally covered by Medicare.”
Despite its prevalence and severity, researchers wrote that there are fewer randomized clinical trials for CKD compared with other chronic diseases, which they said may be attributable to “stakeholder barriers.”
Mussina and colleagues used data from in-center hemodialysis treatments from 2016 to 2018 to perform a pooled analysis of the percentage of patients achieving targets for clinical quality measures and found there no significant differences between 252 facilities with clinical research vs. 2201 facilities without research across seven quality targets (Kt/v, 98.6% vs. 98.6%; foot checks, 93% vs. 92.6%; hemoglobin, 78.9% vs. 78.9%; mineral bone disorder, 48.6% vs. 49.5%; albumin, 34% vs. 33.4%; missed treatments, 19.7% vs. 19.6%; and catheter use, 14.2% vs. 14.7%).
“These insights are of importance to nephrologists, nurses and care teams considering involvement in RCTs that advance care paradigms and the state of nephrology,” researchers wrote.
Collapse
Mussina K. Impact of Conducting Clinical Research on Facility Performance & Quality. Presented at: American Nephrology Nurses Association National Symposium; Aug. 29-31, 2020 (virtual meeting).
Read more about
Click Here to Manage Email Alerts